Return to home page
Searching: Muskingum library catalog
Some OPAL libraries remain closed or are operating at reduced service levels. Materials from those libraries may not be requestable; requested items may take longer to arrive. Note that pickup procedures may differ between libraries. Please contact your library for new procedures, specific requests, or other assistance.
  Previous Record Previous Item Next Item Next Record
  Reviews, Summaries, etc...
EBOOK
Title Obesity management and redux / edited by Stylianos Nicolaidis.
Imprint San Diego : Academic Press, [1997]
©1997

Subject Dexfenfluramine -- Congresses.
Obesity -- Chemotherapy -- Congresses.
Fenfluramine -- pharmacology.
Fenfluramine -- therapeutic use.
Obesity -- drug therapy.
Alt Name Nicolaïdis, Stylianos.
Description 1 online resource (xv, 126 pages) : illustrations
polychrome rdacc
Note digitized 2010 HathiTrust Digital Library committed to preserve pda
Summary Redux is a revolutionary new anti-obesity drug that has just been approved (July 1996) by the FDA. It is the first weight management drug treatment to be launched in the United States in 20 years and is not addictive, unlike earlier drugs used for this purpose. Obesity Management and Redux includes a brief introduction which leads up to its discovery and includes an overview of new trends in obesity management. The book lists the pharmacological profile of the drug, given by experts involved in monitoring the effects of the drug on the brain neurotransmitters, as well as detailing the results (including safety data) of the various clinical trials. Key Features * Covers all aspects of a revolutionary new drug * Lists pharmacological profile of the drug * Includes safety data * Projects future trends in weight management.
Contents M. Derome-Tremblay, The Story of Dexfenfluramine and Its History over the Past 30 Years. S. Nicolaidis and R. Essner, Marketing in the United States: Labeling and Major Marketing Options. G. Bray, New Trends in the Management of Obesity in the U.S. Pharmacological Profile: R. Wurtman, Brain Neurotransmitters. S. Garattini, Neurochemical Mode of Action of Drugs Which Modify Feeding via 5HT System. J. Blundell, Effects on Eating Patternsand Motivation in Humans Methods for Assessing Neurochemical Changes and their Effect: M. Kalia, The Signifcance of DF Induced Neurochemical Changes, 1976 & 150#1995. J. OCallaghan, Glial Reaction as an Indicator of Neurotoxicity. R. Moore, The Long-Term DF Study. S. Lorens, DF Effects on Behaviour. B. Campbell, Pharmacokinetic Consideration in Assessing Neurochemical Changes. Therapeutic Efficacy: G. Cooper and R. Sandage, Overview of the Clinical Data. B. Guy-Grand, The INDEX Study: New Data. R. Noble, An 18-Month Study in Overweight American Patients. G. Faich, PPH/Key Discussion Points. N. Laudignon and M. Rebuffe-Scrive, Overview of the Safety Data. Round Table Discussion: V. Itallie, Benefit/Risk Ration of the Treatment of Obesity.
Bibliography Note Includes bibliographical references.
Access Use copy Restrictions unspecified star
Reproduction Electronic reproduction. [S.l.] : HathiTrust Digital Library, 2010.
System Details Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. http://purl.oclc.org/DLF/benchrepro0212
Note Print version record.
ISBN 008053791X (electronic bk.)
9780080537917 (electronic bk.)
9780125181709
0125181701
1281033413
9781281033413
OCLC # 162128816
Additional Format Print version: Obesity management and redux. San Diego : Academic Press, ©1997 0125181701 9780125181709 (DLC) 96036686 (OCoLC)35657823


If you experience difficulty accessing or navigating this content, please contact the OPAL Support Team